Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Breast Disease | Research article

The effects of Berberis vulgaris consumption on plasma levels of IGF-1, IGFBPs, PPAR-γ and the expression of angiogenic genes in women with benign breast disease: a randomized controlled clinical trial

Authors: Saeed Pirouzpanah, Sanaz Asemani, Ali Shayanfar, Behzad Baradaran, Vahid Montazeri

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

The present study was designed to investigate the effects of Berberis vulgaris (BV) juice consumption on plasma levels of insulin-like growth factor (IGF-1), IGF-binding proteins (IGFBPs), and the expression of PPAR-γ, VEGF and HIF in women with benign breast disease.

Methods

This parallel design randomized, double-blind controlled clinical trial was conducted on 85 eligible patients diagnosed with benign breast disease. They were assigned randomly into either BV juice group (n = 44, BV juice: 480 ml/day) or placebo group (n = 41, BV placebo juice: 480 ml/day) for 8 weeks intervention. Participants, caregivers and those who assessed laboratory analyses were blinded to the assignments. Plasma levels of biomarkers were measured at baseline and after 8 weeks by ELISA. Quantitative real-time PCR was used to measure the fold change in the expression of each interested gene.

Results

The compliance of participants was 95.2% and 40 available subjects analyzed in each group at last. Relative treatment (RT) effects for BV juice caused 16% fall in IGF-1 concentration and 37% reduction in the ratio of IGF-1/1GFBP1. Absolute treatment effect expressed 111 ng/ml increased mean differences of IGFBP-3 between BV group and placebo. Plasma level of PPAR-γ increased in both groups but it was not significant. Fold changes in the expressions of PPAR-γ, VEGF and HIF showed down-regulation in the intervention group compared to placebos (P < 0.05).

Conclusions

The BV juice intervention over 8 weeks was accompanied by acceptable efficacy and decreased plasma IGF-1, and IGF-1/IGFBP-1 ratio partly could be assigned to enhanced IGFBP-1 level in women with BBD. The intervention caused reductions in the expression levels of PPAR, VEGF, and HIF which are remarkable genomic changes to potentially prevent breast tumorigenesis.

Trial registration

IRCT201211051133​5N2. Registered 10 July 2013 (retrospectively registered).
Appendix
Available only for authorised users
Literature
1.
Hartmann LC, Sellers TA, Lingle WL, Degnim AC, Vierkant RA, Maloney SD, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229–37.PubMedCrossRef
2.
Griffin JL, Pearlman MD. Primer on the management of benign breast diseases. Breast Health. 2011;6:127–34.
3.
Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, et al. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer. 2010;126:180–90.PubMedPubMedCentralCrossRef
4.
Lagiou P, Samoli E, Lagiou A, Zourna P, Barbouni A, Georgila C, et al. A comparison of hormonal profiles between breast cancer and benign breast disease: a case–control study. Ann Oncol. 2013;24:2527–33.PubMedPubMedCentralCrossRef
5.
Zhang X, Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res. 2002;62:4369–75.PubMed
6.
Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14:329–41.PubMedCrossRef
7.
Lofqvist C, Chen J, Connor KM, Smith ACH, Aderman CM, Liu N. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A. 2007;104:10589–94.PubMedPubMedCentralCrossRef
8.
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia. Nat Rev Cancer. 2012;2:159–69.CrossRef
9.
Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev. 2006;38:89–116.PubMedPubMedCentralCrossRef
10.
Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17:328–36.PubMedCrossRef
11.
12.
Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 2004;18:528–40.PubMedPubMedCentralCrossRef
13.
Salven P, Perhoniemi V, Tykk H, Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat. 1999;53:161–6.PubMedCrossRef
14.
15.
Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of Tamoxifen. Cancer Res. 2000;60:2898–905.PubMed
16.
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenge. Nat Rev Clin Oncol. 2018;15:325–40.PubMedPubMedCentralCrossRef
17.
Xin X, Rodrigues M, Umapathi M, Kashiwabuchi F, Ma T, Babapoor-Farrokhran S, et al. Hypoxic retinal Müller cells promote vascular permeability by HIF-1–dependent up-regulation of angiopoietin-like 4. PNAS. 2013;10:1–10.
18.
Gilkes DM. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013;9:1623–36.PubMedCrossRef
19.
Dales J, Beaufils N, Silvy M, Picard C, Pauly V, Pradel V. Hypoxia inducible factor 1a gene (HIF-1a) splice variants: potential prognostic biomarkers in breast cancer. BMC Med. 2010;8:44.PubMedPubMedCentralCrossRef
20.
Fatehi M, Saleh TM, Fatehi-Hassanabad Z, Farrokhfal KH, Jafarzadeh M, Davodi S. A pharmacological study on Berberis vulgaris fruit extract. J Ethnopharmacol. 2005;102:46–52.PubMedCrossRef
21.
Javadzadeh M, Ebrahimi A. The traditional uses and pharmacological effects of different parts Berberis Vulgaris (berberine) in Iran. Sci Agric. 2013;1:61–6.
22.
Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park SY. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine. 2010;17:436–40.PubMedCrossRef
23.
Eom KS, Kim HJ, So HS, Park R, Kim TY. Berberine-induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction. Biol Pharm Bull. 2010;33:1644–9.PubMedCrossRef
24.
Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008;22:999–1012.PubMedCrossRef
25.
Kim JB, Ko E, Han W, Shin I, Park SY, Noh DY. Berberine diminishes the side population and ABCG2 transporter expression in MCF7 breast cancer cells. Planta Med. 2008;74:1693–700.PubMedCrossRef
26.
Hamsa TP, Kuttan G. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol. 2012;35:51–70.CrossRef
27.
Lingyi F, Wangbing C, Wei G, Jingshu W, Yun T, Dingbo S. Berberine targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and cytochrome-c/caspase signaling to suppress human cancer cell growth. Plose one. 2013;8:1–13.
28.
Gu Y, Zhang Y, Shi X, Li X, Hong J, Chen J, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010;81:766–72.PubMedCrossRef
29.
Association WM. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.CrossRef
30.
Shamsa F, Monsef H, Ghamooshi R, Verdian-rizi M. Spectrophotometric determination of total alkaloids in some Iranian medicinal plants. Thai J Pharm Sci. 2008;32:17–20.
31.
Pirouzpanah S, Taleban FA, Mehdipour P, Atri M, Hooshyareh-rad A. The biomarker-based validity of a food frequency questionnaire to assess the intake status of folate, pyridoxine and cobalamin among Iranian primary breast cancer patients. Eur J Clin Nutr. 2014;68:316–23.PubMedCrossRef
32.
33.
Chen CM, Chang HC. Determination of berberine in plasma, urine and bile by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995;665(1):117–23.PubMedCrossRef
34.
35.
Zhao HL, Sui Y, Qiao CF, Yip KY, Leung RKK, Tsui SKW. Sustained antidiabetic effects of a berberine-containing chinese herbal medicine through regulation of hepatic gene expression. Diabetes. 2012;61:933–43.PubMedPubMedCentralCrossRef
36.
Kim DI, Lee TK, Lim IS, Kim H, Lee YC, Kim CH. Regulation of IGF-I production and proliferation of human leiomyomal smooth muscle cells by Scutellaria barbata D. Don in vitro: isolation of flavonoids of apigenin and luteolon as acting compounds. Toxicol Appl Pharmacol. 2005;205:213–24.PubMedCrossRef
37.
Ko BS, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull. 2005;8:1431–7.CrossRef
38.
Lamb JJ, Holick MF, Lerman RH, Konda VR, Minich DM, Desai A. Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D3, and vitamin K1 produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome. Nutr Res. 2011;31:347–55.PubMedCrossRef
39.
Suwanichkul A, Allander SV, Morris SL, Powell DR. Glucocorticoids and insulin regulate expression of the human gene for insulin-like growth factor-binding protein-1 through proximal promoter elements. J Biol Chem. 1994;269:30835–41.PubMed
40.
Crowe FL, Key TJ, Allen NE, Appleby PN, Overvad K, Grønbæk H. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European prospective investigation into Cancer and nutrition. Cancer Epidemiol Biomark Prev. 2009;18:1333–40.CrossRef
41.
Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. J Biol Chem. 2006;281(51):39607–19.PubMedCrossRef
42.
Rosendahl AH, Hietala M, Henningson M, Olsson H, Jernström H. IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families. Breast Cancer Res Treat. 2011;127:785–94.PubMedCrossRef
43.
Zumkeller W. IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? J Clin Pathol. 2001;54:285–8.CrossRef
44.
Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer. 2012;131:105–13.CrossRef
45.
Enriori PJ, Fischer CR, Gor JR, Etkin AE, Calandra RS, Luthy IA. Augmented serum levels of the IGF-I/IGF-binding protein-3 ratio in pre-menopausal patients with type I breast cysts. Eur J Endocrinol. 2003;148:177–84.PubMedCrossRef
46.
Aljada AMS. Metformin and neoplasia: implications and indications. Pharmacol Ther. 2012;133:108–15.PubMedCrossRef
47.
Chen Y, Li Y, Wang Y, Wen Y, Sun C. Berberine improves free-fatty-acid–induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator–activated receptor γ and fatty acid transferase expressions. Metab. 2009;58:1694–702.CrossRef
48.
Zhou J, Zhou SH. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol. 2010;649:390–7.PubMedCrossRef
49.
Pham TPT, Kwon J, Shin J. Berberine exerts anti-adipogenic activity through up-regulation of C/EBP inhibitors, CHOP and DEC2. Biochem Biophys Res Commun. 2011;413:376–82.PubMedCrossRef
50.
Feng AW, Gao W, Zhou GR, Yu R, Li N, Huang XL, et al. Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPARγ pathway during acute endotoxemia. Int Immunopharmacol. 2012;12:182–8.PubMedCrossRef
51.
Yin J, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull. 2008;31:1169–76.CrossRef
52.
Kourtidis A, Srinivasaiah R, Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, et al. Peroxisome proliferator-activated receptor-γ protectsERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res Treat. 2009;11:1–11.
53.
Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol. 1995;9:794–804.PubMed
54.
Gao N, Zhao TY, Li XJ. The protective effect of berberine on β-cell lipoapoptosis. J Endocrinol Investig. 2011;34:124–30.CrossRef
55.
Hu Y, Davies GE. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia. 2010;81:358–66.PubMedCrossRef
56.
Kim S, Oh S, Lee J, Han J, Jeon M, Jung T. Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells. Cell Physiol Biochem. 2013;32:1541–50.PubMedCrossRef
57.
Imenshahidi M, Hosseinzadeh H. Berberis Vulgaris and berberine: an update review. Phytother Res. 2016;30(11):1745–64.PubMedCrossRef
58.
Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243(2):449–61.PubMedCrossRef
Metadata
Title
The effects of Berberis vulgaris consumption on plasma levels of IGF-1, IGFBPs, PPAR-γ and the expression of angiogenic genes in women with benign breast disease: a randomized controlled clinical trial
Authors
Saeed Pirouzpanah
Sanaz Asemani
Ali Shayanfar
Behzad Baradaran
Vahid Montazeri
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2715-1

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue

Research article

Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model

Research article

Inhibitory effects of ChondroT and its constituent herbs on RANKL-induced osteoclastogenesis

Research article

Water-separated part of Chloranthus serratus alleviates lipopolysaccharide- induced RAW264.7 cell injury mainly by regulating the MAPK and Nrf2/HO-1 inflammatory pathways

Research article

Anti-obesity effect of Yangkyuksanwha-tang in high-fat diet-induced obese mice

Research article

Ocimum gratissimum Linn. Leaves reduce the key enzymes activities relevant to erectile dysfunction in isolated penile and testicular tissues of rats

Research article

Discovery, synthesis and antibacterial evaluation of phenolic compounds from Cylicodiscus gabunensis